MOLECULAR CHARACTERIZATION OF MICROBIOTA AND ITS RELATIONSHIP TO THE PREVALENCE OF VIRAL AND BACTERIAL ENTERITIS
Project Number: 1235-51000-055-08
Nonfunded Cooperative Agreement
Start Date: May 12, 2009
End Date: May 01, 2014
ARS is interested in determining the impact of health-promoting components in foods including those containing probiotic bacteria. A set of preliminary studies done in Medellin and Bogota, Colombia showed a reduction in Bifidobacterium species in children with diarrhea compared to healthy controls. A more complete clinical diagnosis of the etiology of the diarrhea is needed to support feeding selected probiotics that enhance health-promoting microflora in the intestine. The project plan has one objective that directly relates to this agreement: 1)To elucidate the mechanisms used by probiotic bacteria to improve respiratory and intestinal mucosal responses to allergens, and correlate intestinal microflora composition of pigs and humans with biomarkers of allergic and intestinal disease. The COOPERATOR has received approval from the Ethics Committee from Universidad Javeriana and funding through Banco de la Republica to measure differences in intestinal microflora in children with diarrhea compared to healthy controls. Microflora changes will be tracked by real-time PCR using specific probes for the most common bacterial pathogens (E. coli, Salmonella spp., C. difficile) and viral pathogens such as rotavirus and coronaviruses. Both ARS and the Cooperator will evaluate the modulating effect of probiotic bacteria in children.
ARS will acquire processed clinical samples from the Cooperator (nucleic acids from fecal samples) to validate previous results found in two independent cohort studies with children. This information will be used by both ARS and the Cooperator to jointly develop new research studies that specifically focus on the evaluation of probiotic intervention to prevent onset of diarrhea.